Predictive biomarkers for the efficacy of nivolumab as ≥ 3<sup>rd</sup>-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial.

BMC Cancer · 2022 · PMC8994342 · PMID 35397540

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In this study, although our six patients with EBV ( +) gastric cancer (5 in the nivolumab and 1 in the placebo group) also showed a trend toward a high percentage (4/6, 66.7%) of tumor PD-L1 CPS (≥ 1%) compared with those of patients with EBV ( −) gastric cancer (9/30, 30%), 2 out of 5 EBV ( +) patients in the nivolumab group showed early progressive disease (Figure S 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.